Nature Communications (Sep 2020)
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
- Demet Candas-Green,
- Bowen Xie,
- Jie Huang,
- Ming Fan,
- Aijun Wang,
- Cheikh Menaa,
- Yanhong Zhang,
- Lu Zhang,
- Di Jing,
- Soheila Azghadi,
- Weibing Zhou,
- Lin Liu,
- Nian Jiang,
- Tao Li,
- Tianyi Gao,
- Colleen Sweeney,
- Rulong Shen,
- Tzu-yin Lin,
- Chong-xian Pan,
- Omer M. Ozpiskin,
- Gayle Woloschak,
- David J. Grdina,
- Andrew T. Vaughan,
- Ji Ming Wang,
- Shuli Xia,
- Arta M. Monjazeb,
- William J. Murphy,
- Lun-Quan Sun,
- Hong-Wu Chen,
- Kit S. Lam,
- Ralph R. Weichselbaum,
- Jian Jian Li
Affiliations
- Demet Candas-Green
- Department of Radiation Oncology, University of California Davis
- Bowen Xie
- Department of Radiation Oncology, University of California Davis
- Jie Huang
- Department of Radiation Oncology, University of California Davis
- Ming Fan
- Department of Radiation Oncology, University of California Davis
- Aijun Wang
- Department of Surgery, School of Medicine, University of California Davis
- Cheikh Menaa
- Department of Radiation Oncology, University of California Davis
- Yanhong Zhang
- Department of Pathology, Kaiser Permanente Medical Center Vallejo and Vacaville
- Lu Zhang
- Department of Radiation Oncology, University of California Davis
- Di Jing
- Department of Radiation Oncology, University of California Davis
- Soheila Azghadi
- Department of Radiation Oncology, University of California Davis
- Weibing Zhou
- Department of Radiation Oncology, University of California Davis
- Lin Liu
- Department of Radiation Oncology, University of California Davis
- Nian Jiang
- Department of Radiation Oncology, University of California Davis
- Tao Li
- Department of Radiation Oncology, University of California Davis
- Tianyi Gao
- Department of Radiation Oncology, University of California Davis
- Colleen Sweeney
- Department of Biochemistry and Molecular Medicine, University of California Davis
- Rulong Shen
- Department of Pathology, Ohio State University
- Tzu-yin Lin
- Department of Biochemistry and Molecular Medicine, University of California Davis
- Chong-xian Pan
- NCI-Designated Comprehensive Cancer Center, University of California Davis
- Omer M. Ozpiskin
- Department of Radiation Oncology, University of California Davis
- Gayle Woloschak
- Department of Radiation Oncology, Northwestern University, Feinberg School of Medicine
- David J. Grdina
- Department of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago
- Andrew T. Vaughan
- Department of Radiation Oncology, University of California Davis
- Ji Ming Wang
- Chemoattractant Receptor and Signal Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute
- Shuli Xia
- Department of Neurology, Johns Hopkins School of Medicine
- Arta M. Monjazeb
- Department of Radiation Oncology, University of California Davis
- William J. Murphy
- NCI-Designated Comprehensive Cancer Center, University of California Davis
- Lun-Quan Sun
- Center for Molecular Medicine, Xiangya Hospital, Central South University
- Hong-Wu Chen
- Department of Biochemistry and Molecular Medicine, University of California Davis
- Kit S. Lam
- Department of Biochemistry and Molecular Medicine, University of California Davis
- Ralph R. Weichselbaum
- Department of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago
- Jian Jian Li
- Department of Radiation Oncology, University of California Davis
- DOI
- https://doi.org/10.1038/s41467-020-18245-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
The emergence of tumour adaptive radioresistance can limit the success of radiation therapy and immunotherapy in breast cancer. In this study, the authors demonstrate that CD47 and HER2 are coordinating in tumor response to radiation and that co-blockage of both receptors can eliminate radiorestistant breast cancer cells.
